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Abstract
Each year an estimated 120 million episodes of pneumonia occur in children younger than 5 years of age, resulting in 
one million deaths globally. Within this age group the lungs are still developing by increasing alveoli numbers and airway 
dimensions. Pneumonia during this critical developmental period may therefore adversely affect the lung’s structure 
and function, with increased risk of subsequent chronic lung disease. However, there are few longitudinal studies of 
pneumonia in otherwise healthy children that extend into adulthood to help address this important question. Birth 
cohort, longitudinal, case-control and retrospective studies have reported restrictive and obstructive lung function 
deficits, asthma, bronchiectasis, and chronic obstructive pulmonary disease. In particular, severe hospitalised 
pneumonia had the greatest risk for long-term sequelae. Most studies, however, were limited by incomplete follow-
up, some reliance upon parental recall, risk of diagnostic misclassification, and potential confounders such as nutrition, 
social deprivation, and pre-existing small airways or lungs. More long-term studies measuring lung function shortly 
after birth are needed to help disentangle the complex relationships between pneumonia and later chronic lung 
disease, while also addressing host responses, types of infection, and potential confounding variables. Meanwhile, 
parents of young children with pneumonia need to be advised about the importance of symptom resolution, 
post-pneumonia. In addition, paying attention to factors associated with optimising lung growth such as good 
nutrition, minimising exposure to air pollution, avoiding cigarette smoke, and decreasing the risk of preventable 
infections through good hygiene and having their children fully vaccinated should be emphasised. Finally, in the 
developing world and for disadvantaged communities in developed countries, public health policies leading to good 
quality housing and heating, hygiene, education, and improving socio-economic status are also essential.
Keywords: asthma, bronchiectasis, child, chronic obstructive pulmonary disease, pneumonia
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1. Introduction
        1.1 The burden of pneumonia
Pneumonia is the greatest cause worldwide of childhood 
morbidity and mortality [1]. The most important 
respiratory pathogens implicated in severe and fatal cases 
of childhood pneumonia are Streptococcus pneumoniae 
[2], Haemophilus influenzae type b [3], respiratory 
syncytial virus (RSV) [4], and seasonal influenza virus 
[5], three of which are already targeted by vaccines that 
are licensed currently. In 2010, there were an estimated 
120 million episodes of clinically diagnosed pneumonia 
involving children younger than 5 years of age globally, 
including 14 million with severe disease requiring hospital 
treatment [6]. Of greater concern, in 2013 as many as one 
million children died from pneumonia, accounting for 15% 
of all fatalities in this age group [7]. Most cases (>98%) of 
pneumonia and pneumonia-related deaths (>99%) are 
in developing countries, occurring mostly out of hospital 
and in the first year of life [6]. Nevertheless, pneumonia 
is also important in developed countries, and prior to the 
introduction of pneumococcal conjugate vaccines there 
were an estimated 2.6 million cases of pneumonia annually 
in children aged younger than 5 years, including 1.5 million 
requiring hospitalisation, and 3,000 deaths [8]. However, 
despite high vaccine uptake, disadvantaged indigenous 
children living in these affluent nations still have amongst 
the highest rates of pneumonia recorded [9,10]. In addition 
to the usual recognised risk factors for pneumonia, such as 
household overcrowding, low birthweight and exposure 
to inhaled environmental toxicants, indigenous children 
living in remote communities also experience early and 
heavy nasopharyngeal colonisation by pneumococcal 
serotypes not included in conjugate vaccines [11].
        1.2 Clinical gaps
Despite the high prevalence of pneumonia, including its 
global clinical and economic importance, many gaps remain 
in our understanding and management of pneumonia 
in young children. These gaps, recently summarised in 
several reviews [12–14], include the long-term effects 
of pneumonia and its potential role in adult-focused 
pulmonary disorders [15]. This information is important, 
for not only managing individual patients, but also for 
understanding the true burden of disease, including 
the contribution of early childhood pneumonia to the 
estimated 200 million people with chronic obstructive 
pulmonary disease (COPD) and the 235 million people 
with asthma worldwide [16]. Only then can the full benefit 
of interventions, such as duration and type of antibiotics 
or the introduction of new vaccines into national 
immunisation programmes, be understood. In this review, 
we focus on the long-term (>6 months) consequences of 
pneumonia in children and we exclude studies that relate 
primarily to wheezing illness in children.
2. Pneumonia in young children and subsequent adult 
lung disease
Throughout the last three decades evidence has emerged 
suggesting that adult-onset chronic pulmonary disorders 
are likely to have their origins in early life. Here we review 
the evidence of the published data.
There are two published systematic reviews on the long-
term impact of childhood pneumonia [17,18], with one 
review [17] also including studies relating to bronchiectasis. 
As the authors used different search terms, there were 
both similarities and differences between the two reviews. 
Nevertheless, the Thomson et al [17] review involved two 
additional prospective studies [19,20] on radiographically 
confirmed pneumonia.
In the studies included in the review by Edmonds et al 
[18], a total of 722 children from 13 studies (10 hospital, 
3 community-based birth cohorts) were followed for 
sequelae, 61% of whom were younger than 2 years of 
age at the time of their pneumonia, and none had any 
identifiable pre-existing risk factors for chronic pulmonary 
disorders. Radiographic confirmation of pneumonia was 
available only for the 379 (52%) children included in the 
hospital-based studies. The median length of follow-up 
was 10.8 (interquartile range [IQR] 2.1–17.0) years and 
overall there was a median 34% (IQR 12%–45%) attrition 
rate of study subjects. Seventy-seven cases (10.4%; 95% 
confidence interval [CI] 5.4%–15.4%) were found to 
have major sequelae involving restrictive lung disease, 
obstructive lung disease or bronchiectasis. Meta-analysis 
showed the risk of one of these complications was higher 
in hospitalised (13.6%; 95% CI 6.2%–21.1%) than non-
hospitalised children (5.5%; 95% CI 2.8%–8.3%), whilst 
among the pathogens, adenovirus pneumonia was 
associated with the highest risk (54.8%; 95% CI 39.2%–
70.5%) of developing one of these major sequelae. Of the 
sequelae, restrictive lung disease was the most commonly 
detected (5.5%; 95% CI 2.5%–10.2%). Bronchiectasis, 
either alone (0.9%; 95% CI 0.07%–8.7%) or in combination 
with restrictive lung disease (1.2%; 95% CI 0.05%–7.7%), 
was found only in those who had been hospitalised for 
pneumonia and obstructive lung disease in those with a 
history of severe adenovirus pneumonia (2.8%; 95% CI 
0.18%–6.4%). Nevertheless, in this review lung function 
tests suggesting airway obstruction were also reported in 
up to one-third of 62 South African children 1–7 years after 
their pneumonia [21] and in 14 of 18 (78%) 7–8-year-old 
children with a history of chlamydial pneumonia in early 
infancy [22]. Although children younger than 2 years of age 
had a greater risk of sequelae than those aged 2–5 years at 
the time of their pneumonia, this did not reach statistical 
significance (13.4%; 95% CI 4.5%–22.3% vs 8.7%; 95% CI 
3.1%–14.3% respectively, odds ratio [OR] 1.22 [95% CI 
0.21–7.1]). Furthermore, in the multivariable model only 
hospitalisation remained a major risk factor for sequelae 
(OR 3.65 [95% CI 1.96–6.8]).
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Here, we summarise studies identified from these reviews 
and our own search with a focus on prospective and 
case-control studies. Relevant studies were identified by 
searching the PubMed database using the terms ‘children’ 
and ‘pneumonia’ and ‘long term’, respectively in their 
titles or abstracts without language restrictions. Studies 
published prior to 13 April 2015 were included.
        2.1 Prospective longitudinal and case-control studies
These data are summarised in Tables 1 and 2. Three 
large follow-up, community-based, birth cohort studies 
from the United Kingdom (UK) assessing sequelae in 
non-hospitalised children with clinically diagnosed 
pneumonia were identified. The extracted information for 
two birth cohort studies was from health visitor records 
of infants born between 1920 and 1930 in Hertfordshire 
County, England (males only) [23], and between 1921 and 
1935 in Saint Andrews, Scotland, respectively [24]. The 
surviving participants from both cohorts were evaluated 
when they were aged in their 50s and 60s. The third 
community-based birth cohort study was from the 1958 
British National Child Development Study where, at the 
age 7-year follow-up interview, parents were asked if their 
child ever had pneumonia [25]. Subjects in this study were 
assessed at 34 to 35 years of age. Each of these three birth 
cohort studies reported that pneumonia in early childhood 
was associated with restrictive lung function.
In contrast, two other birth cohorts [26,27] indicated 
pneumonia in early childhood was associated with an 
obstructive rather than restrictive lung function deficit 
(Table 1). The first study was from Derbyshire County, 
England, where records for babies born between 1917 and 
1922 were preserved [26]. These records also included 
their respiratory health, documented by health visitors 
in the first 2 years of life. Overall, 618 of the 1,909 (32%) 
men and women known to have been born in the six 
chosen districts at that time, now aged in their mid-60s 
and 70s, completed health questionnaires and underwent 
spirometry. After adjusting for age, height, smoking, and 
asthma, the 13 men with pneumonia diagnosed before 
age 2 years had significantly lower forced expiratory 
volume in one second (FEV1), forced vital capacity (FVC), 
and FEV1/FVC values than the 315 men without a history 
of pneumonia. The second report was from the Tucson 
Children’s Respiratory Study, United States of America, 
(USA) where 1,246 unselected healthy infants were 
enrolled from 1980 to 1984 and followed into adulthood 
[27,35]. It reported on those with a history of clinically 
diagnosed and radiographically confirmed pneumonia 
during the first 3 years of life [27]. In more than half of 
the original 66 cases, pneumonia was associated with 
respiratory viruses (mainly RSV) and in almost two-thirds 
wheezing was present. None were hospitalised. Forty-
four (67%) of these children were followed as adults into 
their mid-to-late 20s and as a group they had persistently 
impaired lung function with decreased FEV1/FVC ratios 
and reduced mid-expiratory flow rates indicating small 
airway obstruction, which was only partially corrected by 
bronchodilators. Compared to those without pneumonia, 
these young adults had a two-fold increased risk of active, 
physician-diagnosed asthma (OR 1.95 [95% CI 1.11–3.44]).
Other birth cohort studies (Table 1) have also reported 
reduced lung function in adults following childhood 
lower respiratory tract illnesses. The Newcastle Thousand 
Families Study, UK, involved 1,142 infants born in 1947 
and their lower respiratory illnesses were recorded by 
health visitors during the first 5 years of life [30]. Of the 
252 (22%) who were later recruited from this birth cohort 
into a nested case-control study in 1961 and underwent 
spirometry at age 14-years, 122 returned for additional 
assessments at 49–51 years of age (Table 2). Those with 
a history of lower respiratory illnesses before age 5-years 
had significantly lower FEV1 recordings than their healthy 
peers at age 14-years and they also demonstrated a 
greater decline in FEV1 between 14 and 50 years of age. 
Finally, the Barry Caerphilly Growth Study undertaken in 
Barry and Caerphilly, Wales, UK, reported the results of 
spirometry performed on 679 of the original 951 (71%) 
25-year-old subjects born in these two towns between 
1972 and 1974 and from whom research personnel had 
gathered information on upper and lower respiratory 
tract infections during 14 home visits from birth until the 
subjects reached 5 years of age [28]. The major findings 
from this study were that lower respiratory tract infections 
during the first year of life were associated with decreased 
lung function, involving all lung function parameters 
except FVC, suggesting these children were at increased 
risk of airway obstruction. Indeed, a dose-response effect 
was observed and the authors estimated that a two-fold 
increase in lower respiratory tract infections during the 
first year of life was associated with a decrease in FEV1 
equal to that seen with cigarette smoking for 10–17 
pack-years.
        2.2 Retrospective studies
The review by Edmonds and colleagues [18] identified 
seven retrospective studies published between 1971 
and 2000 that reported outcomes for specific pathogens: 
adenovirus [36,37], Mycoplasma pneumoniae [38–40], 
Chlamydia trachomatis [22], and Staphylococcus aureus 
[41]. However, these data cannot be extrapolated to 
‘general pneumonic illnesses’ because of the likely high 
selection bias inherent in such retrospective studies. 
Moreover, none of the studies had searched systematically 
for other co-existing respiratory pathogens that may also 
have contributed to the child’s clinical presentation and 
long-term outcomes.
Many other retrospective studies relating childhood 
respiratory outcomes to poorer adult respiratory health 
have been published and these include population-based 
studies, such as that of Barker and Osmond [42], which 
concluded that there was strong evidence of a direct causal 
link between acute lower respiratory infection in early 
childhood and chronic bronchitis in adult life. Furthermore, 
this study suggested that infection in early childhood had 
a greater influence than cigarette smoking in determining 
the geographical distribution of chronic bronchitis with 
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Study
Country
Year(s) of 
incepti
on
Year(s) of 
study
Source of 
diagnosis
N
o. w
ith  
pneum
onia
N
o. w
ith    
pneum
onia 
studied (%
)
N
o. w
ithout 
pneum
onia 
studied
Ages           
(years)
M
edian 
follow
-up 
(years)
M
ain findings
Barker et al. 
[23] a
U
K
1920–30
1989
Health visitors 
prospecti
ve 
reports of 
illness in the 
first yr, and 
betw
een 1 and 
5 yrs of life
122
b
122 (100)
703
59–67
60
Bronchiti
s or pneum
onia in m
ale infants w
as associated 
w
ith significantly reduced adult values for FEV
1  (-0.17 L; 
95%
 CI -0.32, -0.02) and FV
C (-0.24 L; 95%
 CI -0.24, -0.07) 
and increased odds of w
heezing (O
R 1.83 [95%
 CI 1.05, 
3.20]) independent of sm
oking, birth w
eight and social 
class.
Shaheen et 
al. [24] a
U
K
1921–35
1985–86
D
octors’ 
records for 
the first 5 yrs 
of life
18
10 (53)
229
57.6 ± 4.3
d
50
Pneum
onia in the first 2 yrs of life w
as associated w
ith 
significantly reduced adult values for FEV
1  (-0.39 L; 95%
 
CI -0.67, -0.11; p = 0.007) and FV
C (-0.60 L; 95%
 CI -0.92, 
-0.28); p < 0.001) independent of age, sex, height, sm
oking 
and other illnesses before age 2 yrs.
Johnston et 
al. [25] a
U
K
1958
1992–93
Parents report 
w
hen child 
aged 7 yrs
350
193 (55)
1,199
34–35
30
H
istory of pneum
onia in the first 7 yrs of life w
as 
significantly associated w
ith reduced adult FEV
1  (-0.102 L; 
95%
 CI -0.175, -0.029; p = 0.006) and FV
C (-0.173 L; 95%
 
CI -0.243, -0.067; p = 0.001) w
ithout a change in FEV
1 /FV
C 
rati
os, w
hich w
ere unaltered by bronchodilators and w
ere 
independent of a history of w
heezing.
Shaheen et 
al. [26]
U
K
1917–22
1990–91
H
ealth visitors’ 
reports 
of illness 
collected 3 
m
onthly in 
first yr, then 
once yearly
20
20 (100)
598
67–74
70
In m
en only, pneum
onia before age 2 yrs w
as significantly 
associated w
ith low
er adult FEV
1  (-0.65 L; 95%
 CI -1.02, 
-0.29, p < 0.001), FV
C (-0.51 L; 95%
 CI -0.94, -0.08; p = 0.02) 
and FEV
1 /FV
C rati
os (-10.9%
; 95%
 CI -16.9, -4.8; p < 0.001) 
independent of sm
oking and asthm
a.
Chan et al. 
[27]
U
SA
1980–84
1996–2003
Clinical 
w
ith CXR 
(infiltrates, 
broncho-
pneum
onia or 
pneum
onia) in 
the first 3 yrs 
of life
66
44 (67)
308
26–29
26
Those w
ith pneum
onia before 3 yrs of age had significantly 
low
er FEV
1 /FV
C rati
os (-3.23%
; p = 0.034) ), FEF25-75 
(-0.508 L/s; p = 0.02) and FEF25-75/FV
C rati
os (-11.14%
; 
p = 0.024) at 26 yrs of age, independent of w
heeze and 
sm
oking, and w
hich w
ere only parti
ally reversible w
ith 
bronchodilators. Pneum
onia w
as also associated w
ith a 
tw
o-fold increased risk of acti
vely m
anaged asthm
a at age 
29 yrs (O
R 1.95 [95%
CI 1.11, 3.44]; p = 0.02).
Table 1 Prospecti
ve birth cohort studies exam
ining the eff
ects of childhood pneum
onia upon adult lung functi
on
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Study
Country
Year(s) of 
incepti
on
Year(s) of 
study
Source of 
diagnosis
N
o. w
ith  
pneum
onia
N
o. w
ith    
pneum
onia 
studied (%
)
N
o. w
ithout 
pneum
onia 
studied
Ages     
(years)
M
edian 
follow
-up 
(years)
M
ain findings
Lopez-Bernal 
et al. [28]
U
K
1972–74
1997
Study team
 
or m
aternal 
report of 
respiratory 
illness in the 
first 5 yrs of 
life
c
N
R
N
R
N
R
25.0 ± 0.7
d
25
679 (71%
) of original cohort underw
ent lung functi
on 
testi
ng. A
ft
er adjusti
ng for potenti
al confounding factors, 
low
er respiratory tract infecti
ons in the first yr of life w
ere 
negati
vely associated w
ith all spirom
etry values, except for 
FV
C, and show
ed a significant dose-response eff
ect w
here 
a tw
o-fold increase in low
er respiratory tract infecti
ons 
w
as associated w
ith reduced FEV
1  (-0.078 L; 95%
 CI -0.153, 
-0.03), and FEV
1 /FV
C rati
os (-1.23%
; 95%
 CI -2.22, -0.25).
Colley et al. 
[29]
U
K
1946
1966
Parent 
questi
oned 
w
hen child 
aged 2 yrs 
(pneum
onia, 
broncho-
pneum
onia or 
bronchiti
s)
820
820 (100)
2,502
20
e
20
In ‘never sm
okers’, prevalence of day/night cough w
as 9.1%
 
in group w
ith chest infecti
ons vs 5.2%
 w
ithout. In sm
okers, 
values w
ere 16.5%
 and 13.5%
, respecti
vely. D
iff
erence 
betw
een groups (w
ith and w
ithout chest infecti
ons) w
as 
significant (p < 0.025). Social class and air polluti
on had no 
significant eff
ect.
Table 1 cont.
CI, confidence interval; CXR, chest radiograph; FEV
1 , forced expiratory volum
e in one second; FV
C, forced vital capacity; FEF25-75, forced expiratory flow
 betw
een 25%
 and 75%
 of FV
C; N
R, not reported; O
R, odds rati
o; U
K, 
U
nited Kingdom
; U
SA
, U
nited States of A
m
erica
a Included in review
 by Edm
onds et al. [18]
b M
ales only
c Supplem
ented by a doctor’s diagnosis w
hen available
d M
ean ± Standard D
eviati
on
e  Cohort w
as born in the last w
eek in M
arch 1946. In 1966, they w
ere all sent a questi
onnaire at the sam
e ti
m
e
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Table 2 Case-control and follow
-up studies exam
ining the eff
ects of childhood pneum
onia upon adult lung functi
on
Study
Type of 
study
Country
Year(s) of 
incepti
on
Year(s) of 
study
Source of 
diagnosis
N
o. w
ith 
pneum
onia
N
o. w
ith 
pneum
onia 
studied (%
)
N
o. w
ithout 
pneum
onia 
studied
A
ges (years)
M
edian 
follow
-up  
(years)
M
ain findings
Tennant et 
al. [30] a
Case-control 
(done in 
adolescence 
and again in 
adulthood)
U
K
1947
1961–62, 
1996–98
D
octor or study 
team
 diagnosis 
of severe low
er 
respiratory 
illness before 5 
yrs of age
167
167 (100)
85
1449–51
1450
Severe low
er respiratory illness before age 
5 yrs w
as independently associated w
ith 
low
er FEV
1  at 14 yrs of age (p = 0.004) and a 
greater overall decline in FEV
1  betw
een 14 to 
51 yrs of age (p = 0.047).
M
ok &
 
Sim
pson 
[31] b
Case-control
U
K
1971–74
1978–81
Infants 
hospitalised 
w
ith CXR 
docum
ented
51
51 (100)
51
c
7.20 ± 0.44
d
7
O
ngoing respiratory sym
ptom
s in the 
previous year w
ere significantly higher in 
the pneum
onia group than controls. This 
included w
heeze (p < 0.01), chest infecti
ons 
(p < 0.001), using m
edicati
ons (p < 0.001) 
and school m
issed from
 respiratory illness 
(p < 0.01). Study also had 102 children 
hospitalised w
ith bronchioliti
s and 44 w
ith 
bronchiti
s. Com
pared w
ith controls, those 
w
ith bronchioliti
s had significantly low
er 
FEV
1  (p < 0.05), but not FV
C values. A
lthough 
findings w
ere sim
ilar in pneum
onia group, 
the diff
erence w
as not stati
sti
cally significant.
Eastham
 et 
al. [19] b
Controlled 
follow
-up 
study
U
K
1995–98
N
R
Clinical w
ith CXR 
confirm
ati
on 
aged 5–16 yrs
159
103 (65)
248
e
N
R
5.6
(4.4–7.4) e
Pneum
onia is independent risk factor for 
persistent cough (O
R 2.9 [95%
 CI 1.45, 5.71; 
p = 0.02) and asthm
a (O
R 4.8 [95%
 CI 1.43, 
16.34]) in cases w
ith non-atopic parents. 
Com
pared to controls, cases w
ith pneum
onia 
and atopic parents had significantly low
er 
FEV
1 %
 pred (-7.0%
; 95%
 CI -10.5, -3.21; p < 
0.001) and FV
C %
 pred (-4.4%
; 95%
 CI -8.0, - 
0.78; p = 0.017).
Pulchalski et 
al. [32] b,f
Case-control
Gam
bia
1992–94
N
R
Children aged <5 
yrs w
ith severe 
pneum
onia
190
g
68 (36)
67
h
12–14
13
N
o significant diff
erence found betw
een 
cases and controls. 14 of the 83 traced had 
died of w
hom
 78%
 died w
ithin days to w
eeks 
of discharge.
Piippo-
Savolainen 
et al. [33] f
Case-control
Finland
1981–82
2000
CXR-confirm
ed 
hospitalised 
children aged 
1–24 m
ths
44
34 (77)
45
18–21
17
N
o significant diff
erence betw
een groups 
for lung functi
on, diagnosis of asthm
a, or 
prolonged cough in last 12 m
ths. Study also 
enrolled infants w
ith bronchioliti
s (n = 53) 
group that significantly diff
ered from
 controls 
for asthm
a sym
ptom
s (O
R 5.07 [95%
 CI 1.66, 
15.50]) and abnorm
al lung functi
on (O
R 4.13 
[95%
 CI 1.36, 12.51]).
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Study
Type of 
study
Country
Year(s) of 
incepti
on
Year(s) of 
study
Source of 
diagnosis
N
o. w
ith 
pneum
onia
N
o. w
ith 
pneum
onia 
studied (%
)
N
o. w
ithout 
pneum
onia 
studied
A
ges (years)
M
edian 
follow
-up  
(years)
M
ain findings
W
esley et al. 
[21] b,f
Follow
-up of 
hospitalised 
cohort
South Africa 
(‘Black 
children’)
N
R
N
R
CXR-confirm
ed, 
aged 6–119 
m
ths, but m
ost 
w
ere from
 virus 
or m
easles
N
R
62
0
N
R
7
40%
 had persistent respiratory sym
ptom
s 
(w
heeze or cough), 34%
 w
ith abnorm
al 
lung functi
on (8%
 w
ith obstructi
on, 16%
 
undefined).
Kycler et al. 
[20] b
Follow
-up of 
hospitalised 
cohort
Poland
N
K
i
N
K
i
55
49 (89)
0
N
R
(2–10) e
44 of 55 had spirom
etry: 35%
 restricti
ve 
patt
ern, 17%
 airw
ay obstructi
on. 13%
 of 
cohort w
ere rehospitalised for respiratory 
illness, 35%
 had exercise lim
itati
on.
Chang et al. 
[34] b
Follow
-up of 
hospitalised 
cohort
Australia 
(A
boriginal 
children)
2000–01
2001–02
Clinical w
ith CXR 
confirm
ati
on 
(alveolar 
changes) aged 
<14 yrs
109
88 (81)
0
N
R
1
37.5%
 w
ith persistent CXR abnorm
ality or 
respiratory sym
ptom
s, 62.5%
 w
ithout these 
features.
Table 2 cont.
CI, confidence interval; CXR, chest radiograph; FEV
1 , forced expiratory volum
e in one second; FV
C, forced vital capacity; O
R, odds rati
o; N
K, not know
n; N
R, not reported; pred, predicted; U
K, U
nited Kingdom
a severe low
er respiratory tract infecti
on according to m
aternal report, fam
ily physician or study team
b Included in review
 by Thom
son et al. [17]
c Controls from
 sam
e gender and class as index child
d M
ean ± Standard D
eviati
on
e Range
f Included in review
 by Edm
onds et al. [18]
g O
nly 83 of the 190 cases could be traced
h Gender and age m
atched controls
i U
nable to obtain arti
cle in Polish (data from
 abstract)
108
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national time trends reflecting the influence of both 
factors [42]. Most retrospective studies are consistent 
with the longitudinal studies’ findings that early childhood 
lung infections are associated with future lung disease or 
poorer lung function in adults [17,18,26–29].
        2.3 Studies focused on bronchiectasis only
The rarer complication of bronchiectasis is characterised 
by chronic wet or productive cough, periodic infectious 
exacerbations, and irreversible bronchial dilation and 
wall thickening seen on either plain radiographs or 
computed tomography of the chest [43]. It normally has 
multiple aetiologies, including prior severe infections, 
immune deficiencies, and primary ciliary dyskinesia, and 
its pathogenesis remains poorly understood. However, 
bronchiectasis in children from indigenous communities 
and developing countries is associated with preterm 
delivery and episodes of early and recurrent pneumonia 
during infancy [44–47], while 30–60% of adults with 
recently diagnosed bronchiectasis report repeated lower 
respiratory tract infections during childhood [48–50]. It 
is hypothesised that severe pneumonia, including that 
resulting occasionally from adenovirus outbreaks, can 
damage ciliated airway epithelium in the growing lung, 
impairing airway clearance defences and setting up a 
cycle of repeated or persistent infection and inflammation 
involving airway infiltration by activated neutrophils and 
CD4+ T-lymphocytes, followed by degradation of bronchial 
wall supporting structures, bronchial dilatation, and 
ultimately bronchiectasis [51]. Nevertheless, studies that 
identified severe respiratory infections during childhood 
as risk factors for bronchiectasis were also retrospective 
and relied upon patient recall or involved highly specific 
patient groups [48–50]. Readers are referred to the review 
by Thomson et al [17] that included studies specifically 
relating to bronchiectasis post-pneumonia.
3. Possible explanations for long-term effects
        3.1 Early lung growth and development
During normal fetal development and the first 3–4 years 
of rapid post-natal growth, the developing lungs are most 
vulnerable to injury by infectious and non-infectious insults, 
including reprogramming by various gene–environment 
interactions [52,53]. It is during the early post-natal 
period, when new alveoli are still forming and post-natal 
lung growth is most rapid, that the developing lungs are 
most susceptible to the long-term effects of pneumonia. 
Lung development occurs over five phases, the first 
four of which are in utero, and all five phases can be 
influenced by maternal, genetic, and environmental 
factors, including infection in the critical post-natal growth 
and alveolarisation period [54,55]. Within the developing 
embryo the lung buds first appear between 4 and 7 weeks, 
the conducting airways are established by 17 weeks 
and the respiratory zone, which includes the respiratory 
bronchioles and alveolar ducts, is fully developed by 
27-weeks gestation. Alveolar sacs first emerge, followed 
by alveoli, after 28 weeks and at full term 100–150 million 
alveoli have formed. After birth the alveoli continue to 
multiply reaching the estimated adult number of 300–600 
million by at least 3–4 years of age. The alveoli also increase 
in volume and the airways keep growing, doubling their 
size by the end of adolescence in females and the mid-
twenties for males [55]. During the intrauterine period 
and the first few years of life various environmental insults 
to the developing lung may adversely impact upon future 
respiratory health. For example, preterm delivery can 
interrupt lung development with subsequent maturation 
occurring out of phase compared with those born at full 
term, and the resulting airways are smaller with fewer 
alveoli and potential negative influences upon lung 
function [52,56].
Respiratory infections with consequent inflammatory 
responses may interrupt the critical alveolarisation phase 
of lung development, restricting alveolar numbers and/or 
size and leading to often mild, but impaired lung growth. 
The association between pneumonia and obstructive lung 
disease is possibly through similar mechanisms to those 
leading to bronchiectasis, which is an obstructive lung 
disease. Lung infections at the peak periods of somatic 
lung growth (a normal newborn has only approximately 
5% of a healthy adult’s alveolar surface area [57]) may 
also alter the programming of lung development at a local 
or systemic level. The effects of early infection, especially 
viral lower respiratory tract infections, upon lung growth, 
programming and future lung function disease types are 
beyond the scope of this review and readers are referred 
to the respiratory literature [55,56,58].
        3.2 Other confounders and effects
In addition to the effects of lower respiratory infections, 
maternal smoking, and other maternal factors, nutrition, 
and allergic sensitisation can have potential negative 
influences upon lung function [52,56,59,60]. Of the above 
factors, solid experimental evidence on the impact of poor 
nutrition [61,62] and tobacco smoking in animals [63–65] 
support the association studies in human literature where 
infants who are poorly nourished or exposed to tobacco 
smoke (both in utero and in early life) are more likely to 
have lung infections and are also independently more likely 
to have adult lung disease and/or poorer lung function 
[53,55,56]. In animal studies these effects are reversible 
(at least partially) since improvement in nutrition early 
in life results in better adult lung development [66]. 
Pre- and post-natal tobacco exposure have independent 
long-term pulmonary effects [67,68] and cessation of 
tobacco exposure improves the accelerated decline in lung 
function [69]. While it is beyond the scope of this review 
to elaborate upon these factors (see reviews [60,66,67]), 
readers should be cognisant of the importance of these 
issues. The potential reversibility of impaired lung growth 
and function also highlights the opportunities for future 
interventions.
An alternative interpretation is that, irrespective of 
external factors, lung function from infancy tracks 
throughout childhood into adult life meaning those 
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predisposed to COPD, bronchiectasis, and other adult lung 
dysfunction are destined to do so, with pneumonia simply 
being a biomarker for those with underlying abnormal 
lung function and growth. Consequently, it follows that no 
interventions will alter the future development of adult 
lung disease. This rather nihilistic view is, however, unduly 
pessimistic. Although randomised controlled trial evidence 
in humans is not available (and likely never will be), there 
are many biological reasons why this opinion is incorrect. 
Examples include marked improvements in survival and 
lung function seen in patients with cystic fibrosis over the 
last two decades [70], the reversibility (at least partially) 
seen in animal studies described above [60,66], and the 
reduction in mortality from pneumonia through improved 
case management [7]. Indeed, it is highly likely that the 
interactions are complex since the host’s respiratory 
microbiome, immune responses, epigenetic influences, 
and their physical environment are being recognised 
increasingly as playing a role in the human phenotypes 
of health and disease [71]. As shown recently for RSV in 
unselected term infants [72], both possibilities may not 
be mutually exclusive. Thus infants with smaller airways 
and/or reduced numbers of alveoli at birth could have 
greater numbers of lower respiratory tract infections, 
including pneumonia, during the critical post-natal period 
and these infections might also lead to further disruption 
of alveolar multiplication and/or airway growth and 
development.
At this point it is also worth noting that recent studies 
report up to 40% of adults with a chronic productive cough 
and ‘difficult to control’ asthma may have radiographic 
evidence of underlying bronchiectasis [73], while 29–58% 
of those with severe COPD also have bronchiectasis as 
either a direct complication of COPD or part of an overlap 
syndrome [74,75]. These reports highlight the complex 
relationships observed between early childhood respiratory 
infections and chronic airway disorders in adults. There 
may be at least two different processes operating in these 
circumstances producing either functional (COPD) and/or 
structural (bronchiectasis) defects. A clue to the presence 
of these mechanisms was provided by a recent prospective 
study of respiratory exacerbations in infants with cystic 
fibrosis detected by a newborn screening program [76]. 
The overall exacerbation rate in the first 2 years of life 
was negatively associated with FEV1 at 5 years of age, 
suggesting airway remodelling, while only the severe 20% 
of exacerbations requiring hospitalisation were associated 
with structural airway injury causing bronchiectasis at age 
5-years.
        3.3 Case ascertainment issues
An important limitation for many studies was the reliance 
upon parental reporting of symptoms and that some of the 
cases may have had bronchiolitis, virus-induced wheezing 
or asthma rather than pneumonia. Even when the diagnosis 
of pneumonia is supported by radiographic evidence it can 
still be difficult to differentiate between patchy pulmonary 
infiltrates and localised atelectasis from mucous plugs 
in non-hospitalised children with moderate, and often 
viral, lower respiratory tract illnesses [27]. Radiographic 
abnormalities (including alveolar consolidation) are often 
present in infants with moderate-to-severe bronchiolitis 
[77] and many of the studies relating lower respiratory 
infections to long-term outcomes do not report on, or do 
not exclude, presence of wheeze in the study population. 
The respiratory physiology of wheeze in infants, which 
is more likely to occur when abnormally small airways 
and/or atopic sensitisation are present, is probably going 
to be different to that of pneumonia, which is primarily 
a parenchymal illness. Consequently, as these diseases 
have different underlying pathologies and pathogenetic 
mechanisms, they are also very likely to have different 
long-term outcomes [59,78,79].
4. Studies strengths and weaknesses
The major strengths of the community-based birth cohort 
studies are the recruitment of unselected subjects and 
their longitudinal nature spanning several decades, which 
allowed prospectively collected infant and early childhood 
exposure data to be analysed with those describing adult 
respiratory outcomes [23–28,30]. Important limitations 
though are losses to follow-up, which included those who 
had died shortly after discharge from hospital [32] and 
from chronic pulmonary disorders, such as COPD in the 
older aged cohorts [23,42], as well as those who were too 
unwell to attend or to perform satisfactory lung function 
tests. One study assessed only men [23], while those lost to 
follow-up were usually socioeconomically disadvantaged 
and may have been at greater risk of respiratory morbidity, 
even if they had never smoked [80,81]. The early birth 
cohorts were also conducted before antibiotics were 
available. Thus the nature or likelihood of injury to the 
developing lung during alveolarisation may differ whether 
or not cases of bacterial pneumonia received antibiotics.
Despite the birth cohort studies being prospective, the 
respiratory illness data were generally collected by visiting 
healthcare workers, usually some weeks or months 
later, and in one study up to 7 years after the event [25]. 
Consequently, the diagnosis of pneumonia often relied 
upon parental recall and in only one of these community-
based studies was the diagnosis of pneumonia made 
by a paediatrician and confirmed radiographically [27]. 
Moreover, most studies provided little information on the 
number of pneumonia episodes experienced at an individual 
level, limiting our capacity to determine if a single episode 
in an infant or young child is associated with impaired lung 
function in later adult life or if instead pneumonia needs 
to be severe or recurrent to have such effects. In addition, 
the subjects in some studies were asked to self-report 
some potentially important confounding variables, such as 
gestation at delivery, maternal smoking, and occupational 
exposures to environmental toxicants. As discussed above, 
an unknown proportion of these episodes may have been 
from bronchiolitis, virus-induced wheeze, or asthma 
rather than pneumonia. Thus, these studies suffered 
from varying degrees of potential selection, gender 
and recall bias, as well as diagnostic misclassification. 
Also, as with any observational studies, the possibility 
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of residual unmeasured confounding remains an issue. 
 
The hospital-based studies reported in the systematic 
review [18] involved small numbers of subjects (20–190), 
of whom 19–59% were followed for a mean of 7.8 (range 
1.5–17) years. All those reporting upon a single respiratory 
pathogen (S. aureus, M. pneumoniae and C. trachomatis) 
were retrospective. Each study was limited by incomplete 
data collection, failure to use sensitive diagnostic 
techniques to exclude co-infection by other respiratory 
pathogens, likely referral bias, and differential patient 
follow-up where the potential existed for children with 
symptoms to be more likely to be brought back for review. 
Finally, other major limitations were the lack of baseline 
clinical and lung function data prior to the episode of 
pneumonia in all but one study [27] and the lack of data 
on potential confounders and the effect of interventions 
provided.
5. Conclusions and future directions
It is widely recognised that pneumonia in young children 
causes a considerable worldwide burden of mortality 
and short-term morbidity in survivors. What is less well 
known is that infectious insults to the rapidly growing 
and still developing lungs in the first 1–3 years of life 
are independently associated with an increased risk of 
impaired lung function in adulthood. The risks appear 
greatest for those whose illness is of sufficient severity 
to warrant treatment in hospital. The long-term effects 
associated with early childhood pneumonia include 
restrictive or obstructive lung function deficits and an 
increased risk of adult asthma, non-smoking related 
COPD, and bronchiectasis. The studies underpinning these 
observations do however have important limitations. 
They are a mixture of prospective and retrospective 
studies, involving both community- and hospital-based 
populations experiencing illness of varying severity, with 
incomplete follow-up and opportunities for sampling 
and recall bias, and diagnostic misclassification of 
bronchitis, bronchiolitis, viral-induced wheezing and 
asthma as pneumonia. Most important of all is that most 
studies do not have prior lung function data for their 
pneumonia cases and subsequent impairments in lung 
function might simply reflect pre-existing abnormalities 
in already susceptible infants and young children. 
 
More high-quality, long-term studies are needed, 
ideally involving birth cohorts from both developing 
and developed countries with antenatal recruitment 
and, whenever feasible, measurements of lung function 
should be conducted shortly after birth. To minimise the 
risk of misclassification, standardised diagnostic criteria 
for pneumonia should also be used. Such studies are 
challenging and expensive to perform, but can help focus 
future research, while helping to guide clinical practice 
and child public health policies. A promising start has 
been made in South Africa with the Drakenstein Child 
Health Study [82]. Although, by relying solely upon 
the World Health Organization clinical definitions of 
pneumonia many of the cases will have lower airway, 
rather than alveolar involvement, and thus several of the 
questions raised in this review will not be addressed by 
this birth cohort study. The underlying airway cellular, 
immunological, and microbiological mechanisms 
associated with chronic pulmonary disorders originating 
in the antenatal and early childhood periods are also 
important, but beyond the scope of this review and 
are discussed elsewhere [54–59,83]. However, gaining 
an understanding of these mechanisms is vital for 
developing effective therapeutic interventions to either 
prevent or reverse lifelong injury to the developing lungs. 
Meanwhile, for clinicians it is important to recognise that 
young children with pneumonia are at risk of chronic 
pulmonary disease as adults, irrespective whether this 
is a direct result of their infection or that susceptibility 
to pneumonia itself is a marker for potential underlying 
deficits in lung function. Either way, a careful history 
should be taken for each patient, recording details of the 
pregnancy, nature and timing of the birth, maternal and 
household tobacco smoking history, exposure to indoor 
(e.g. biomass fuels) and outdoor air pollution, prior 
history of respiratory symptoms, especially chronic cough, 
wheezing or breathing difficulties, previous respiratory 
illness episodes, their nutritional state, immunisation 
record and personal and family histories of atopy, asthma 
or other chronic lung diseases. The parents and caregivers 
should be counselled about the possibility of adult-onset 
lung disease in the child and advised accordingly of the 
importance of avoiding active and passive smoking, 
indoor and outdoor air pollution, future occupational 
inhalant exposures, and ensuring that all recommended 
vaccines are received in a timely manner. Public health 
interventions, such as appropriate housing, household 
heating and hygiene, reducing barriers to accessing 
healthcare and immunisation services, promoting 
education, and improving socio-economic status are also 
important [29,84], especially in developing countries and 
the economically disadvantaged in developed countries 
(e.g. indigenous populations in Australia, New Zealand, 
Canada, and the USA with high burdens of lung disease 
[85]).
Finally, it is essential that the complex relationships 
between pre-existing lung impairment, early childhood 
pneumonia, and chronic pulmonary disorders in adults 
are disentangled and better understood so that policy 
makers can make informed decisions about public health 
interventions to help stem the tide of chronic lung disease 
in adults. As an example, it will be necessary to take 
into account that vaccines against common respiratory 
pathogens may have longer-term benefits than simply 
protecting against episodes of acute pneumonia. By 2030, 
COPD is predicted to become the third leading cause of 
deaths globally [86], and with almost half of the cases 
now occurring in adults who have never smoked, the 
roles played by exposure to other inhaled environmental 
toxicants and lower respiratory tract infections during 
early childhood need to be highlighted, investigated, and 
managed at both an individual and population level [87].
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